ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / TPST / earnings
BLRX (46) LTRN (31) CALC (38) PHIO (37) ⌘ Pro Terminal →

Tempest Therapeutics Inc. (TPST) Next Earnings Date & Expected ±12.5% Move

$0.47 -4.74% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.47

Tempest Therapeutics Inc. (TPST) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $9.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TPST Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TPST stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Tempest Therapeutics Inc. (NASDAQ: TPST) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.47 (-4.74% 1D, market cap $9.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, TPST ranks #650 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TPST compare to BLRX and LTRN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TPST carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BLRX (BioLineRx Ltd.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $9.9M) and LTRN (Lantern Pharma Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $9.9M). Among the 5-stock peer group, TPST leads on earnings multiple (N/A) while TPST leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TPST?
▼

Per TPST's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001544227), Tempest Therapeutics Inc. generated $74.4M in revenue (-36.8% YoY), -$26.3M in net income, and -$26.8M in free cash flow against $16.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.47 (-1.04%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510034
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (6)Whales (5)SEC (10)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.6% Base Target
$11 Bull$0 Base$0 Bear
📬 FREE TPST RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TPST)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY TPST SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 32.2 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
42
Grade D$0.68-14.7% Next Q
Q2 (-2Q)
39
Grade E$0.58-12.1% Next Q
Q3 (-1Q)
37
Grade E$0.51-7.8% Next Q
Current
34
Grade E$0.47-8.7% Hist 90D α
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TPST Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TPST currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.80) and Max Pain ($0.49) forces dealer call-delta covering toward $10.96.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TPST• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TPST Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.06 Expected Swing
$1.00 (-12.5%)Spot $0.47$0.53 (+12.5%)
MODEL EARNINGS SETUP GAUGE

TPST Quantitative Pre-Earnings Setup: 34/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (34/100)Model Risk Weight (66/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$74.4M-$26.3M-$26.8M52%
FY 20242024-12-31$117.7M-$41.8M-$33.5M52%
FY 20232023-12-31$81.6M-$29.5M-$27.4M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TPST)

  • ✓Walkthrough of TPST's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
TPST // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -77.73%📐 HORIZONTAL RANGE
2026-11-03O $0.54H $0.54L $0.47C $0.47VOL 163.5K
RES: $1.57SUP: $0.12SMA50: $0.80SMA200: $1.48
$5.93$4.45$2.97$1.49$0.01RES $1.57SUP $0.12$0.472026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TPST Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TPST Butterfly Map → + Track TPST →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -36.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on TPST today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TPST. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TPST today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TPST)

Health Care Rank #650 of 1015 ⚔️ BLRX vs TPST Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TPST vs. BLRX, LTRN, CALC, PHIO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Tempest Therapeutics Inc. (TPST) ranks #650 by composite RQD confidence (34/100, grade E) and #892 by equity capitalization ($9.9M). Within this direct 5-issuer industry benchmark cohort, TPST leads on earnings valuation at N/A trailing P/E, while TPST leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BLRX currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with TPST at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
TPST ACTIVE
Tempest Therapeutics Inc.
E 34/100 — — -35.0% -4.74% $9.9M Benchmark Subject
BLRX
BioLineRx Ltd.
D 46/100 — — — -1.51% $9.9M /blrx-vs-tpst →
LTRN
Lantern Pharma Inc.
E 31/100 — — -35.0% -3.15% $9.9M /ltrn-vs-tpst →
CALC
CalciMedica Inc.
D- 38/100 — — -35.0% -4.11% $10.0M /calc-vs-tpst →
PHIO
Phio Pharmaceuticals Corp.
D- 37/100 — — -35.0% +2.33% $10.0M /phio-vs-tpst →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001544227 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Tempest Therapeutics Inc. (TPST) reported GAAP revenue of $74.4M (-36.8% vs. FY2024 revenue of $117.7M , and -8.9% cumulative change since FY2023) , GAAP net income of -$26.3M, operating cash flow of -$26.8M, and free cash flow of -$26.8M (+19.8% YoY). On the balance sheet, TPST closed FY2025 with $16.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $74.4M -$26.3M -$26.8M -$26.8M $16.9M —
FY2024 (FY) 2024-12-31 $117.7M -$41.8M -$33.0M -$33.5M $41.5M $0
FY2023 (FY) 2023-12-31 $81.6M -$29.5M -$27.4M -$27.4M — —

3. TPST Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TPST stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Tempest Therapeutics Inc. (NASDAQ: TPST) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.47 (-4.74% 1D, market cap $9.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, TPST ranks #650 in composite RQD confidence.

How does TPST compare to BLRX and LTRN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TPST carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BLRX (BioLineRx Ltd.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $9.9M) and LTRN (Lantern Pharma Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $9.9M). Among the 5-stock peer group, TPST leads on earnings multiple (N/A) while TPST leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TPST?

Per TPST's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001544227), Tempest Therapeutics Inc. generated $74.4M in revenue (-36.8% YoY), -$26.3M in net income, and -$26.8M in free cash flow against $16.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TPST trading relative to its 50-day, 200-day, and 52-week technical levels?

TPST last traded at $0.47 (-4.74% on volume of 160,457 shares), positioning the stock -41.25% below its 50-day simple moving average ($0.80) and -68.24% below its 200-day simple moving average ($1.48). Across its 52-week range of $0.49 to $10.44, TPST sits at the 0.0% percentile with a 14-day RSI of 32.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.53).

Direct Sub-Reports: TPST RQD Cockpit TPST 12M Forecast TPST Earnings & Move TPST Dividends & DRIP TPST Insiders & 13F TPST Whale Options TPST Profit Sankey TPST News & Why
ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

TPST — Tempest Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Tempest Therapeutics Inc. (TPST) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.47 (-4.74% 1D, market capitalization $9.9M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Tempest Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Tempest Therapeutics Inc. (TPST) reported $74.4M in annual revenue (up from $117.7M in FY2024, -36.8% YoY) and -$26.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($81.6M revenue, -$29.5M net income) through FY2025, TPST scaled operating cash flow to -$26.8M and free cash flow to -$26.8M, backed by $16.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $0.49 – $10.44 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies, sector correlations, or proprietary signals are mapped for TPST.

  • Key Question #1: Can TPST sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $74.4M and free cash flow of -$26.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is TPST's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

TPST Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Tempest Therapeutics Inc. (TPST) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TPST Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TPST Bull vs. Bear Conversation Board — What's Your Call at $0.47?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TPST 🐻 33% BEARISH CONVICTION
1. Pick Your Side on TPST:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $0.59 (+18.0%)
📌 Pinned Debate

The stock trades at a $10.7M market capitalization with a 0.5 Debt/Equity ratio and an Altman Z-Score of 2.5, a forensic balance sheet

Don't sleep on TPST's setup in Health Care. The stock trades at a $10.7M market capitalization with a 0.5 Debt/Equity ratio and an Altman Z-Score of 2.5, a forensic balance sheet reading that sits above distress territory.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (34/100) backs up the fundamental quality.

ArenaChamp_24 🐂 BULL

@MacroHawk_NYC Agree on the RQD 34/100 quality, though with 1.0 beta I'm scaling in with half-size at $0.50 and keeping dry powder in case we test $0.47.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $0.42 (-16.0%)
Spot @ $0.50

Reported net losses of -$26.3M in FY 2025 against $7.7M of cash, with ROIC at -35% and free cash flow yield at 0%, point to a cash-burn

Sitting on the sidelines or leaning short TPST above $0.50. Reported net losses of -$26.3M in FY 2025 against $7.7M of cash, with ROIC at -35% and free cash flow yield at 0%, point to a cash-burn profile the RQD rating scores as vulnerable.. Until Fundamental Cash Engine (6/20) and FCF yield (0.0%) inflect higher, upside is capped near $10.44.

LIVE TAPE